Vaccines and Infectious Diseases
Specialist early-phase vaccine expertise
Vaccine and infectious disease trials demand speed, scientific precision, and careful risk management particularly in early-phase development where safety, immunogenicity, and proof-of-concept data are foundational to what follows.
At Southern Star Research, our Medical Monitors bring site-level experience in vaccine research, including experience as Principal Investigators across tens of vaccine trials – in addition to their medical monitor roles. This depth of site-level experience is held across both of our Medical Monitors, not a single individual. It is not common in early-phase CROs – and it meaningfully shapes how we approach safety, protocol interpretation, and sponsor communication from the start.
We have achieved contracting through to site initiation visit (SIV) in approximately three months on vaccine programmes. That start-up pace is not the exception here – it reflects a team and a regulatory environment that are genuinely aligned to move.
Indication experience
Why Australia for vaccine clinical trials?
Australia offers a uniquely strong environment for vaccine research, beyond the standard regulatory and cost advantages:
Hemispheric seasonal differences
Australia’s southern hemisphere timing allows continuous global vaccine development for annual-circulation pathogens, enabling earlier data collection for sponsors running year-round programmes.
An industry geared for rapid research
The site network, CRO ecosystem, and regulatory framework in Australia are specifically optimised for early-phase speed and quality.
Multicultural population diversity
Data generated in Australia has broader global applicability than data from more homogeneous populations.
Streamlined CTN regulatory pathway
Significantly compressed start-up compared to the US or EU.
R&D tax incentives
Materially reducing development costs for emerging biotech sponsors.
FDA and EMA acceptance of Australian data